AUTL
Autolus Therapeutics plc
$1.58
+0.00 (+0.00%)
At close · Jul 2
Market Cap
$420.53M
Shares
266,155,786
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.58
Open$1.60
Day$1.57–1.72
52W$1.18–2.70
Avg vol 30d1.1M
Short int13.5M · 5.1% float · 10.2d
Short vol36%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+3% above
◦
Price vs 50-day avg
−1% below
◦
RSI (14)
49 · neutral
+
MACD trend
positive
◦
52-week position
27% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $2 › 200d $2 — 50d above 200d
−
Institutional flow
-6% holders QoQ · +9 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
5.06% of float · ▲ +5.4% MoM · 10.2 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
84 holders — mid 3-yr range
Fundamentals
Fair
+
Revenue growth
+496% Y/Y
−
EPS growth
−26% Y/Y
−
Free cash flow
$-302.6M
+
Balance sheet
net cash $104.1M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 16, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 14, 2026
AUCATZYL net product revenue
· full year 2026
Initiated
$120M – $135M
prior FY $75.39M
midpoint +69.1% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+3% above
Bullish
Price vs 50-day avg
−1% below
Neutral
RSI (14)
49 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
27% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.06% of float · ▲ +5.4% MoM · 10.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
84 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 27%
52-wk high $3
vs 200-day avg +3%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AUTL
this stock
Autolus Therapeutics plc
|
$420.53M | -20.6% | +496.0% | — | 5.1% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AUTL | -0.6% | -2.5% | -17.3% | -1.3% | -20.6% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -2.1% | -1.2% | -25.3% | -1.0% | -29.8% |